• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 5, Issue 1
  3. Authors

Online ISSN: 2515-8260

Volume5, Issue1

Dolutegravir, Second Generation Integrase Inhibitor: A New Hope for HIV Patient

    Geeta Yadav Piyush Kumar Yugal Kumar Pradeep Kumar Singh

European Journal of Molecular & Clinical Medicine, 2018, Volume 5, Issue 1, Pages 20-29

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Undeterred efforts are reported and still continue in future to achieve the goals of virologic suppression in HIV-infected individuals. Dolutegravir is the result of all the efforts made in this direction. It is a recent integrase inhibitor drug approved by the US FDA (Food and Drug Administration) for use in the treatment-naïve and treatment-experienced HIV-infected patients. This article has reviewed all the aspects of the drug, including the structural and functional analyses, in vitro activity, pharmacokinetics, drug-drug interactions, MOA, metabolism, excretion, dosing/adverse effects and resistance profile. Dolutegravir is a potent and well tolerated antiretroviral agent that can play an important role in the treating patients harboring resistance to other antiretrovirals. Some new combinations of drug with other antiretrovirals are also in the pipeline that can increase the immunologic response of the HIV patients.
Keywords:
    Dolutegravir Antiretroviral Integrase inhibitor human immunodeficiency virus (HIV)
  • PDF (985 K)
  • XML
(2018). Dolutegravir, Second Generation Integrase Inhibitor: A New Hope for HIV Patient. European Journal of Molecular & Clinical Medicine, 5(1), 20-29.
Geeta Yadav; Piyush Kumar; Yugal Kumar; Pradeep Kumar Singh. "Dolutegravir, Second Generation Integrase Inhibitor: A New Hope for HIV Patient". European Journal of Molecular & Clinical Medicine, 5, 1, 2018, 20-29.
(2018). 'Dolutegravir, Second Generation Integrase Inhibitor: A New Hope for HIV Patient', European Journal of Molecular & Clinical Medicine, 5(1), pp. 20-29.
Dolutegravir, Second Generation Integrase Inhibitor: A New Hope for HIV Patient. European Journal of Molecular & Clinical Medicine, 2018; 5(1): 20-29.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 197
  • PDF Download: 265
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus